CoChat
Sign Up
Cited by 21Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and TreatmentsOvarian cancer diagnosis and treatment

Higher Gemcitabine Dose Was Associated With Better Outcome of Osteosarcoma Patients Receiving Gemcitabine‐Docetaxel Chemotherapy

Lee, Jun Ah, Jeon, Dae‐Geun, Cho, Wan Hyeong, Song, Won Seok, Yoon, Hoi Soo, Park, Hyeon Jin, Park, Byung Kiu, Choi, Hyoung Soo +14 more·2016·Pediatric Blood & Cancer
DOI 10.1002/pbc.26058
Open this paper in CoChat — free account

Abstract

Background: Efficacy of gemcitabine and docetaxel (GEM + DOC) chemotherapy in patients with recurrent or refractory osteosarcoma was evaluated. Methods: Data of 53 patients from 9 institutions, who received GEM (675 or 900 mg/m 2 on days 1 and 8) and DOC (100 mg/m 2 on day 8), were retrospectively reviewed. Results: GEM + DOC was administered as adjuvant (n = 25) or palliative chemotherapy (n = 28). Patients received a median 3 courses (range, 1−10 courses). Objective response rate (CR + PR, where CR is complete response and PR is partial response) and disease control rate (CR+ PR + SD, where SD is stable disease) were 14.3% and 28.6%, respectively. Disease control rate was higher in patients receiving 900 mg/m 2 GEM than in patients receiving 675 mg/m 2 (50.0% vs. 12.5%, P = 0.03). Higher GEM dose was associated with better survival, both in adjuvant (1‐year overall survival, 90.9 ± 8.7% vs. 38.5 ± 13.5%, P = 0.002) and palliative settings (50.0 ± 14.4% vs. 31.3 ± 11.6%, P = 0.04). Conclusions: Further studies are necessary to investigate the efficacy of more aggressive and higher doses of GEM + DOC chemotherapy in osteosarcoma.

Integrity signals

Registry

Crossref · 10.1002/pbc.26058

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • These chemotherapy regimens are recommended based on phase II trials or retrospective studies with small numbers of patients showing moderate response rates of 20-50%.

    “These chemotherapy regimens are recommended based on phase II trials or retrospective studies with small numbers of patients with osteosarcoma showing moderate response rates of 20-50% 142,143,144 .”

    From Osteosarcoma (2022) · cites this paper as [143]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Lee, J. A., Jeon, D., Cho, W. H., Song, W. S., Yoon, H. S., Park, H. J., Park, B. K., Choi, H. S., Ahn, H. S., Lee, J. W., Yoo, K. H., Sung, K. W., Koo, H. H., Kang, H. J., Park, K. D., Shin, H. Y., Koh, K., Im, H. J., Seo, J. J., Lim, Y. J., Baek, H. J., & Kook, H.
Affiliations
  • Samsung Medical Center (KR)
  • Department of Orthopedic Surgery Korea Cancer Center Hospital Seoul Republic of Korea
  • Kyung Hee University (KR)
  • National Cancer Center (KR)
  • Seoul National University Bundang Hospital (KR)
  • Seoul National University (KR)
  • Asan Medical Center (KR)
  • Chungnam National University (KR)
  • Chonnam National University (KR)
Corresponding author
Lee, Jun Ah
ORCID
Venue
Pediatric Blood & Cancer
Publisher
Wiley
Published
2016-05-16
Volume
63
Issue
9
Pages
1552-1556
ISSN
  • 1545-5009 (ISSN-L)
  • 1545-5017
DOI
10.1002/pbc.26058
OpenAlex
W2394953145
Cited by
21
References
20
Citations by year
2026: 2 · 2025: 1 · 2024: 2 · 2023: 1 · 2022: 3 · 2020: 3 · 2019: 2 · 2018: 4 · 2017: 3
FWCI
2.68
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Pediatric Blood & Cancer (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Rheumatology › Bone Tumor Diagnosis and Treatments
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
Keywords
osteosarcoma, gemcitabine, docetaxel, dose escalation, recurrent osteosarcoma, adjuvant chemotherapy, palliative chemotherapy, objective response rate, disease control rate, overall survival
MeSH terms
Docetaxel, Gemcitabine, Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Child, Deoxycytidine, Female, Humans, Male, Retrospective Studies, Osteosarcoma, Taxoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review